ABSTRACT
demonstrated the efficacy of levothyroxine suppression therapy in shrinking nodules. 4, 5, 6 However, there are also studies which showed contradicting results 7, 8 thus making the appropriate course of action controversial. Results could be affected by several factors such as the degree of suppression and the individual's iodine supply status. Thus, one study recommended combining thyroid hormone suppression therapy with iodine therapy on the premise that iodine plays an important role in the pathogenesis of thyroid nodules. 4 Despite government efforts in iodine food fortification to reduce iodine deficiency in the Philippines, certain areas of the country remain iodine deficient. Among these areas is the Davao region where children six to twelve years old still have mild iodine-deficiency disease. 9 Data regarding the use of iodine for thyroid nodules especially in combination with levothyroxine is lacking in the Philippines and even in Asian countries. The use of iodine alone or in combination with levothyroxine is not even part of the treatment options recommended in our local guidelines for thyroid nodule management. 10 The study by Grussendorf 4 comparing levothyroxine with and without iodine showed reduction in the size of nodules in nodular non-toxic goiter. Validating foreign recommendations against local data is an important step in ensuring the best clinical practices for important diseases.
To the best of our knowledge, there has been no placebo-controlled trial using levothyroxine with iodine therapy for nodular goiters in our locality, which is known to be mildly iodine deficient. We aim to replicate the study of Grussendorf 4 by comparing levothyroxine alone and in combination with iodine on thyroid nodule volume reduction.
METHODS

Research Design
This was a double-blind, randomized, placebo-controlled trial conducted in the Ear, Nose, Throat -Head and Neck Surgery (ENT-HNS) outpatient department of the Southern Philippines Medical Center (SPMC) from April 2016 to December 2016 with approval of the Department of Health (DOH) Region XI Cluster Ethics Review Committee.
Participants
Adults aged 18 to 60 years old, euthyroid, with at least one thyroid nodule in a normal-sized or enlarged thyroid were considered for inclusion. The nodules had to be histopathologically benign on fineneedle aspiration biopsy (FNAB) and not more than 3ml in volume. Excluded were patients with prior thyroid stimulating hormone (TSH) suppression therapy within the last six (6) months, purely cystic nodules, those with contraindications to iodine, those with previous use of iodine-containing medications within the last 6 weeks, or who underwent radioactive iodine/surgery, and patients with acute illness and co-morbidities. Figure 1 outlines the screening, randomization and follow up of participants.
Randomization and Interventions
After obtaining informed consent from participants, we gathered baseline demographic and clinical data including age, sex, family history of goiter, thyroid nodule volume, thyroid gland volume and TSH value.
A randomization list was prepared and given to a nurse assistant who assigned the treatment for groups A and B and prepared treatments according to the randomization list. Placebo pills were identical in appearance to iodine pills. Patients were randomly assigned to either one of the following treatment arms: 
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The nurse also dispensed the treatment drugs. The investigators and participants were blinded to treatment arms. Randomization codes were secured until analysis of all data was completed.
TSH suppressive dosage was computed using the participant's weight x 2.1-2.4, depending on the degree of suppression. Levothyroxine (LT4) doses were adjusted for a TSH target range of <0.1mU/L.
Four visits were performed: screening (V1), randomization (V2), and two follow-up visits under therapy after 3 (V3) and 6 months (V4). At V1, V3 and V4, sonography was performed by a blinded radiology consultant who was an ultrasound specialist, using Arietta U70 HITACHI with a 7.5-or 10-MHz transducer (HIMEX Corporation, Japan). The same blinded sonologist measured the thyroid size and thyroid nodule volume all throughout the study period. TSH was measured at V1, V3, and V4 in a central laboratory under regular external quality control. At each follow-up, a pill diary and any unused medications were collected and counted to estimate patient compliance.
Data was tabulated using a predesigned, pretested form. Independent variables included demographic factors such as age, sex, family history of thyroid disease and the assigned treatment group. The main outcome measure was the volume reduction of nodules measured by ultrasound. Resolution was defined as complete disappearance of previously described nodule for the duration of the study. Significant nodule volume reduction was defined as reduction of at least 20% of nodule volume from the baseline for the duration of the study. Furthermore, the different side effects encountered while taking the drug were reported.
Statistical Analysis
Main outcome include mean change in thyroid nodule volume from baseline to 6 months. Continuous data such as age, TSH values, thyroid nodule volume, thyroid gland volume at baseline, 3 months and 6 months were summarized as means ± standard deviations. Comparison of means between the 2 treatment groups were performed using paired t-test. Categorical data such as sex, number of nodules, family history and percentage of decrease in nodule volume at end of 6 months were summarized using frequencies and percentages, and comparison of proportions between the 2 treatment groups was performed using Chi-square test or Fisher exact test. A two-tailed p-value of < .05 was considered statistically significant. All statistical tests were done using Epi Info 7.1.4.0 (CDC, Atlanta, GA, USA). Missing continuous data were filled in by last-observation-carried-forward method.
RESULTS
Patient Characteristics
A total of 47 patients were screened but only 19 patients, aged 19-54 years old (44 nodules) were included in the study. A total of 28 patients were excluded following exclusion criteria. The 19 patients recruited into the trial were randomized either to the levothyroxine + placebo group (n of patients=9; n of thyroid nodules=21) or to the levothyroxine with iodine group (n of patients=10; n of thyroid nodule=23). There were 4 dropouts from the levothyroxine alone group for the duration of the study comprising 3 patients with data up to 3 months only and 1 patient who was lost to follow-up on the 3 rd month. There was also one patient from the levothyroxine with iodine group who failed to have repeat ultrasound on the 6 th month and was lost to follow-up. Four patients belonging to the levothyroxine with iodine group and 3 patients belonging to the levothyroxine alone group were noted to be poorly compliant with the intervention. Of the adverse effects, only palpitations were reported by 16% (3 out of 19) of participants, 1 from the levothyroxine alone group and 2 from the levothyroxine with iodine group.
Baseline characteristics of the 19 patients are shown in Table 1 . There was no significant difference in baseline characteristics between the two groups except for age (p=.018).
A total of 44 nodules were observed during the study. There were 23 nodules examined from the LT4 + iodine group (n of patients=10) with a mean volume of 0.89 ± 0.95 ml and 21 nodules in the LT4 + placebo group (n of patients=9) with a mean volume of 0.89 ± 0.88 ml (p=.988).
Patient Follow up
On the third month, one patient (having one nodule) from the levothyroxine + placebo group was lost to follow up. By the sixth month post-intervention, a total of three patients (having 11 nodules) from the levothyroxine + placebo group were lost to follow up. Hence, perprotocol analysis of the outcome measures only included 5 patients (9 nodules) from the levothyroxine + placebo group. No drop-outs were seen on the levothyroxine + iodine group.
Thyroid Nodule Volume
The mean change in volume from baseline to six months of levothyroxine + iodine group showed a trend of decreasing size of the nodule as compared to levothyroxine + placebo group, -0.010 ± 1.250 (CI -0.521 -0.501) versus 0.507 ± 1.128 (CI 0.025 -0.990), however this was not statistically significant (p=.158). (Table 2) ORIGINAL ARTICLES
Thyroid Gland Volume
A trend of decreasing thyroid gland volume from baseline to six months was also seen in the levothyroxine + iodine group as compared to the levothyroxine + placebo group, -1.291 ± 4.874 (CI -3.427 -0.845) versus 1.467 ± 4.059 (CI -0.408 -3.342) and but this was not significant (p=.068). (Table 2) TSH Suppression TSH suppression from baseline to six months when comparing both groups, was well suppressed in the levothyroxine + placebo group with mean change in TSH of -0.937 ± 0.812 and a confidence interval of -1.467 to -0.406 (p-value for change .007*) and -0.256 ± 0.733 for the levothyroxine + iodine group (CI -0.711 -0.199). However, this was not statistically significant. (p=.072). (Table 2) Greater Than 20% Reduction
Greater than 20% nodule volume reduction was noted in 10/21 (47.6%) nodules for the levothyroxine + iodine group as compared to 7/21 (33.33%) for the levothyroxine + placebo group, (granting all dropouts had the outcome), with 4/48 (8.33%) without any change in volume. However, this was not statistically significant (Chi-square value of 1.96, df = 2, p = .375). (Table 3 )
Resolution
Resolution was noted in five out of twenty-three (21.74%) nodules from the levothyroxine + iodine group as compared to 13/21 (61.90%) from the levothyroxine + placebo group, granting all dropouts had the outcome. This is statistically significant with p-value of .007*. However, this was not the same with per protocol analysis excluding the dropouts, where only 1/9 (11.11%) nodules showed resolution with p-value of .648** (chi-square 7.3259), which was not statistically significant when both groups were compared.
Adverse Effects
Twenty percent (2/10) of patients in the iodine group complained of palpitations in the first month of intervention, compared to 11% (1/9) of patients from the placebo group. This patient complaint led to dose adjustment of levothyroxine that could be well tolerated. For patients who could not tolerate suppressive doses without experiencing palpitations, doses were tapered as tolerated. No other adverse effects were observed in both groups.
New Nodule Formation
It was worth noting that for the duration of six months of treatment for both groups, 4 new nodules were found in 2 patients (1 nodule Table 3 . Distribution of percent change in thyroid nodule volume between the two treatments Chi square 1.96, df=2 p = .375
